Aemetis, Inc. (NASDAQ:AMTX) Stake Boosted by Barclays PLC

Barclays PLC raised its holdings in shares of Aemetis, Inc. (NASDAQ:AMTX) by 14.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,492 shares of the specialty chemicals company’s stock after purchasing an additional 6,996 shares during the period. Barclays PLC’s holdings in Aemetis were worth $146,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of AMTX. JPMorgan Chase & Co. lifted its position in shares of Aemetis by 515.9% in the 4th quarter. JPMorgan Chase & Co. now owns 120,716 shares of the specialty chemicals company’s stock worth $325,000 after buying an additional 101,116 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Aemetis during the 4th quarter valued at about $203,000. Russell Investments Group Ltd. raised its stake in Aemetis by 684.5% during the fourth quarter. Russell Investments Group Ltd. now owns 78,191 shares of the specialty chemicals company’s stock worth $210,000 after acquiring an additional 68,224 shares during the period. SG Americas Securities LLC acquired a new position in Aemetis in the fourth quarter valued at approximately $87,000. Finally, Bank of New York Mellon Corp boosted its stake in Aemetis by 29.6% in the fourth quarter. Bank of New York Mellon Corp now owns 91,880 shares of the specialty chemicals company’s stock valued at $247,000 after acquiring an additional 20,961 shares during the period. 27.02% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMTX has been the topic of a number of research reports. UBS Group dropped their price target on Aemetis from $2.50 to $2.20 and set a “buy” rating on the stock in a research report on Friday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Aemetis in a research note on Friday, March 14th. Ascendiant Capital Markets boosted their price target on shares of Aemetis from $18.00 to $19.00 and gave the company a “buy” rating in a report on Monday, March 17th. Finally, StockNews.com raised shares of Aemetis to a “sell” rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $13.18.

Aemetis Stock Performance

Shares of AMTX stock opened at $1.51 on Wednesday. Aemetis, Inc. has a 1 year low of $1.22 and a 1 year high of $4.73. The business’s fifty day moving average is $1.59 and its 200-day moving average is $2.37. The stock has a market cap of $80.51 million, a PE ratio of -0.67 and a beta of 1.47.

Aemetis (NASDAQ:AMTX) last released its earnings results on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.08). The company had revenue of $42.89 million during the quarter, compared to analysts’ expectations of $59.35 million. During the same quarter in the prior year, the firm posted ($0.58) earnings per share. Equities research analysts predict that Aemetis, Inc. will post -2.07 earnings per share for the current year.

Aemetis Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.